Accustem Sciences (ACUT) Net Cash Flow (2022 - 2026)
Accustem Sciences (ACUT) posted quarterly Net Cash Flow of -$1722.0 for Q1 2026, down 105.5% year-over-year from $31335.0 in Q1 2025, and down 271.92% quarter-over-quarter from -$463.0 in Q4 2025.
Accustem Sciences (ACUT) Net Cash Flow (2022 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Net Cash Flow for 5 consecutive years, with -$1722.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 105.5% year-over-year to -$1722.0; the TTM figure through Mar 2026 stood at -$24175.0 (down 189.51% YoY), while the FY2025 annual figure was $8882.0, up 154.05% from the prior year.
- Net Cash Flow fell to -$1722.0 in Q1 2026 per ACUT's latest filing, from -$463.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $3.2 million in Q1 2022 and bottomed at -$1.3 million in Q2 2022.
- Historically, Net Cash Flow has averaged $718.06 across 5 years, with a median of -$16950.0 in 2025.
- Annual changes were most pronounced in 2023 — Net Cash Flow plunged 117.05% — and 2025, when it jumped 358.8%.
- Accustem Sciences' Net Cash Flow stood at -$597982.0 in 2022, then jumped by 91.72% to -$49529.0 in 2023, then surged by 35.32% to -$32033.0 in 2024, then jumped by 98.55% to -$463.0 in 2025, then sank by 271.92% to -$1722.0 in 2026.
- Business Quant data shows ACUT's Net Cash Flow at -$1722.0 in Q1 2026, -$463.0 in Q4 2025, and -$16950.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | 721.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,722.00 |
| Mar 31, 2026 | -1,722.00 |
| Dec 31, 2025 | -463.00 |
| Dec 31, 2025 | -463.00 |
| Sep 30, 2025 | -16,950.00 |
| Sep 30, 2025 | -16,950.00 |
| Jun 30, 2025 | -5,040.00 |
| Jun 30, 2025 | -5,040.00 |
| Mar 31, 2025 | 31,335.00 |
| Mar 31, 2025 | 31,335.00 |
| Dec 31, 2024 | -32,033.00 |
| Dec 31, 2024 | -32,033.00 |
| Sep 30, 2024 | -8,992.00 |
| Sep 30, 2024 | -8,992.00 |
| Jun 30, 2024 | 36,699.00 |
| Jun 30, 2024 | 36,699.00 |
| Mar 31, 2024 | -12,108.00 |
| Mar 31, 2024 | -12,108.00 |
| Dec 31, 2023 | -49,529.00 |
| Dec 31, 2023 | -49,529.00 |